Search

everythinglearnresearchcommunity

for

Search:↓

ALRN-6924 may prevent hair loss caused by chemotherapy.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Ixekizumab has known and some unexpected side effects.

Cialis and Finasteride could be repurposed to treat aggressive melanoma.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Cetuximab can cause eyelash growth, which is rare but manageable.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

A new combination of tadalafil and finasteride improves drug performance and stability.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Blocking mTORC1 reduces skin tumor growth in mice.

Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Low fucosylation boosts stem cell growth in the eye.

Janus kinase inhibitors may help treat lichen planopilaris.